Last reviewed · How we verify
Loperamide hydrochloride + simethicone chewable tablet
Loperamide hydrochloride acts on opioid receptors in the gut to slow down intestinal motility, while simethicone reduces surface tension in gas bubbles to facilitate their elimination.
Loperamide hydrochloride acts on opioid receptors in the gut to slow down intestinal motility, while simethicone reduces surface tension in gas bubbles to facilitate their elimination. Used for Symptomatic relief of diarrhea, including traveler's diarrhea and acute nonspecific diarrhea, Relief of bloating and discomfort associated with excess gas.
At a glance
| Generic name | Loperamide hydrochloride + simethicone chewable tablet |
|---|---|
| Sponsor | Xian-Janssen Pharmaceutical Ltd. |
| Drug class | Antidiarrheal and antifoaming agent |
| Target | μ-opioid receptors, gas bubbles |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Loperamide binds to μ-opioid receptors in the gastrointestinal tract, reducing peristalsis and increasing water absorption, which helps to alleviate diarrhea. Simethicone works by breaking up gas bubbles into smaller ones, making it easier for them to pass through the digestive system.
Approved indications
- Symptomatic relief of diarrhea, including traveler's diarrhea and acute nonspecific diarrhea
- Relief of bloating and discomfort associated with excess gas
Common side effects
- Constipation
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: